NCT05427305View on ClinicalTrials.gov

TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

549

Participants

Timeline

Start Date

October 20, 2017

Primary Completion Date

March 24, 2020

Study Completion Date

March 24, 2020

Conditions
Efficacy
Interventions
DRUG

TAB008

15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death

DRUG

Bevacizumab

15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death

Trial Locations (1)

215024

TOT, Suzhou

All Listed Sponsors
lead

BioDlink Biopharm Co., Ltd.

INDUSTRY

NCT05427305 - TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter